Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
about
Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsVitamin D and Immune Response: Implications for Prostate Cancer in African AmericansPersistent androgen receptor addiction in castration-resistant prostate cancerInsights into Chemoresistance of Prostate CancerThe endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaPAutophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cellsClinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerThe prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways.Cavin-1/PTRF alters prostate cancer cell-derived extracellular vesicle content and internalization to attenuate extracellular vesicle-mediated osteoclastogenesis and osteoblast proliferation.Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model.Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and UnGenetic variation in RNASEL associated with prostate cancer risk and progression.Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transitionA phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer.Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.Suppression of mucin 2 promotes interleukin-6 secretion and tumor growth in an orthotopic immune-competent colon cancer animal modelClinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients.Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinomaFrom transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cellsAndrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth.Prostate cancer as a model for tumour immunotherapy.Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouseAndrogen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalkAndrogen receptor signaling in prostate cancer development and progression.WMAXC: a weighted maximum clique method for identifying condition-specific sub-network.Biomarkers of fatigue related to adjuvant chemotherapy for breast cancer: evaluation of plasma and lymphocyte expression.miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)-Induced Cancer at Multiple SitesSystemic cytokine levels and subsequent risk of gastric cancer in Chinese Women.Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression.The effects of 1,4-dimethylpyridine in metastatic prostate cancer in miceLinking obesogenic dysregulation to prostate cancer progression.Association between interleukin-6 polymorphisms and urinary system cancer risk: evidence from a meta-analysisProstate cancer markers: An update.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling
P2860
Q24746259-F0B3C344-2291-4CF8-9C60-D3E11AB42E5AQ26750672-98A0BF13-FDF5-4E48-A14B-BD6C77EBCB6AQ26768536-15AEB002-FA90-4982-9851-84A4A312E5C5Q26777163-C698AEB6-F3C0-4210-845D-B754A4C39854Q26795589-168325BC-7A59-4396-9EB8-E3B66CC2BC48Q27348356-C2596B0B-46FB-4544-828E-16028D44B2DDQ28344474-7CD5ED8F-BF9F-46DD-A592-EAD8D6811401Q28539820-6E45D2D0-A3F0-41F9-B497-839045643892Q33389676-F5C2298A-3C08-475D-A8A8-0655673870D3Q33412361-CB224E4F-51B6-48BE-B7A9-8A837D98C359Q33813233-AD01F4E0-0F70-4661-A7BF-8B1C031AC716Q33829429-96A832AF-614A-4D46-97AD-C2354ED20573Q34048411-05685D84-8401-46D7-A371-D812DE43BE9AQ34094981-0BDDD435-8FC0-4678-BC21-9C19DC95F20FQ34243311-64866CF1-4C98-454B-9352-5CEE1DED7CACQ34432864-203D150A-583B-4AAF-B8C9-9AE67E39ED0EQ34483617-418E8643-CF07-4493-A56A-63C4865CEC4CQ34556778-126B8765-B275-41A1-89B5-5784E0701357Q34611172-E6700998-962C-4D1D-8DC8-D5CAB26AFE5AQ34690727-4324892E-CAB0-4892-8B5C-5369EE66E3FDQ34691678-F9B92FEC-3D07-461A-8A60-FBDDB2B96088Q34714834-30CB75E8-64F0-43B6-B03B-405FBDA094B4Q34856875-3B3D5AB4-EB98-4556-9A22-F4DE566942E6Q34917061-E006E7E0-6260-4814-AB79-62A5406A4CA3Q35092971-89A3111E-E4BA-455A-AA5B-3E245C4FD786Q35183663-FDF79B64-0D1D-4A97-AE6E-4A2B771D6E3BQ35229964-262752C9-6898-477B-8DCA-17964AA172B8Q35264807-360EE57B-7A3E-4226-A873-932E0C123C07Q35794952-FA972597-6653-4E44-9799-9BEF7EB301E3Q35873154-7786F94F-84E4-4645-9390-7271D46AF76EQ35925218-E12433C0-2C19-47A1-A57F-7617940C35EFQ35950606-929059E8-A71C-4DA7-88F6-B503781FD67DQ35963362-F959F08E-EF7D-4171-8A76-D08A310A15FEQ35996208-2675A799-F4BC-4E40-B8E1-A68BC823A46DQ36300102-EAB40B5B-6A94-4750-A7B8-98F955C093E8Q36300793-429E4229-AB78-4CA8-9DF5-A707D73C2890Q36525733-686D1E05-D564-4C3E-8AC2-22179877F50AQ36640109-36651B18-4DE7-4007-AD08-289307BF5D7CQ36759374-F5537D00-1451-4DED-9EB3-229EA7E69A9AQ36879620-B3FDDF4B-D871-4EA5-9519-6BD9112CB5D4
P2860
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Elevated levels of circulating ...... etastatic prostatic carcinoma.
@en
Elevated levels of circulating ...... etastatic prostatic carcinoma.
@nl
type
label
Elevated levels of circulating ...... etastatic prostatic carcinoma.
@en
Elevated levels of circulating ...... etastatic prostatic carcinoma.
@nl
prefLabel
Elevated levels of circulating ...... etastatic prostatic carcinoma.
@en
Elevated levels of circulating ...... etastatic prostatic carcinoma.
@nl
P2093
P1476
Elevated levels of circulating ...... etastatic prostatic carcinoma.
@en
P2093
P304
P356
10.1097/00005392-199901000-00051
P407
P577
1999-01-01T00:00:00Z